logo-loader
viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd uplists to OTCQB Venture market from Pink Sheets

The move will allow the Canadian antibody discovery firm to woo more US investors

OTC logo
The British Columbia-headquartered company provides global antibody services ranging from target analysis to pre-clinical studies

Shares of ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) will kick off trading Thursday on the OTCQB Venture market after uplisting from the more speculative Pink Sheets.

The move will allow the Canadian antibody discovery firm to woo more US investors and boost its liquidity.

“As ImmunoPrecise gains recognition for its best-in-class full-service, therapeutic antibody discovery company, we are experiencing increased interest from investors across North America and other International markets,” said Lisa Hebling, chief financial officer.

READ: ImmunoPrecise Antibodies shares up as it launches new antibody discovery platform with US pharma group

"Our listing on the OTCQB allows for better access to the U.S. investment community, greater international visibility, and improved liquidity," Hebling added.

The British Columbia-headquartered company provides global antibody services ranging from target analysis to pre-clinical studies.

READ: ImmunoPrecise Antibodies sees 56% increase in 3Q revenue as it continues to advance business

The company’s attention is fixed on discovering and delivering the most relevant next-generation antibodies, with the highest probability of succeeding through clinical validation.

It recently opened a new office in Cambridge, Massachusetts that will be staffed at first for sales and business development and will take advantage of the Cambridge area’s focus on biotech and pharmaceuticals.

ImmunoPrecise closed at US$0.58 in New York on Wednesday.

Contact Ellen Kelleher at [email protected]

 

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 0.55 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $37.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City. Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia...

on 04/02/2019

2 min read